COVID-19 Vaccination and Clinical Outcomes at a Secondary Referral Hospital During the Delta Variant-dominant Period in West Sumatra, Indonesia
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The second wave of coronavirus disease 2019 (COVID-19) cases in Indonesia, during which the Delta variant predominated, took place after a vaccination program had been initiated in the country. This study was conducted to assess the impact of COVID-19 vaccination on unfavorable clinical outcomes including hospitalization, severe COVID-19, intensive care unit (ICU) admission, and death using a real-world model.Methods: This single-center retrospective cohort study involved patients with COVID-19 aged ≥18 years who presented to the COVID-19 emergency room at a secondary referral teaching hospital between June 1, 2021 and August 31, 2021. We used a binary logistic regression model to assess the effect of COVID-19 vaccination on unfavorable clinical outcomes, with age, sex, and comorbidities as confounding variables.Results: A total of 716 patients were included, 32.1% of whom were vaccinated. The elderly participants (≥65 years) had the lowest vaccine coverage among age groups. Vaccination had an effectiveness of 50% (95% confidence interval [CI], 25 to 66) for preventing hospitalization, 97% (95% CI, 77 to 99) for preventing severe COVID-19, 95% (95% CI, 56 to 99) for preventing ICU admission, and 90% (95% CI, 22 to 99) for preventing death. Interestingly, patients with type 2 diabetes had a 2-fold to 4-fold elevated risk of unfavorable outcomes.Conclusions: Among adults, COVID-19 vaccination has a moderate preventive impact on hospitalization but a high preventive impact on severe COVID-19, ICU admission, and death. The authors suggest that relevant parties increase COVID-19 vaccination coverage, especially in the elderly population.
Abstract
Objectives: The second wave of coronavirus disease 2019 (COVID-19) cases in Indonesia, during which the Delta variant predominated, took place after a vaccination program had been initiated in the country. This study was conducted to assess the impact of COVID-19 vaccination on unfavorable clinical outcomes including hospitalization, severe COVID-19, intensive care unit (ICU) admission, and death using a real-world model.Methods: This single-center retrospective cohort study involved patients with COVID-19 aged ≥18 years who presented to the COVID-19 emergency room at a secondary referral teaching hospital between June 1, 2021 and August 31, 2021. We used a binary logistic regression model to assess the effect of COVID-19 vaccination on unfavorable clinical outcomes, with age, sex, and comorbidities as confounding variables.Results: A total of 716 patients were included, 32.1% of whom were vaccinated. The elderly participants (≥65 years) had the lowest vaccine coverage among age groups. Vaccination had an effectiveness of 50% (95% confidence interval [CI], 25 to 66) for preventing hospitalization, 97% (95% CI, 77 to 99) for preventing severe COVID-19, 95% (95% CI, 56 to 99) for preventing ICU admission, and 90% (95% CI, 22 to 99) for preventing death. Interestingly, patients with type 2 diabetes had a 2-fold to 4-fold elevated risk of unfavorable outcomes.Conclusions: Among adults, COVID-19 vaccination has a moderate preventive impact on hospitalization but a high preventive impact on severe COVID-19, ICU admission, and death. The authors suggest that relevant parties increase COVID-19 vaccination coverage, especially in the elderly population.
참고문헌 (40)
- Clemente-Suárez VJ, "The impact of the COVID-19 pandemic on social, health, and economy", Sustainability, 13(11), pp.6314~ (2021)
- "Daily progress of positive confirmed cases of COVID-19 in Indonesia" (2023)[URL]
- V’kovski P, "Coronavirus biology and replication : implications for SARS-CoV-2", Nat Rev Microbiol, 19(3), pp.155~170 (2021)
- Dyer O, "Covid-19 : Indonesia becomes Asia’s new pandemic epicentre as delta variant spreads", BMJ, 374, pp.n1815~ (2021)
- Chu DT, "COVID-19 in Southeast Asia : current status and perspectives", Bioengineered, 13(2), pp.3797~3809 (2022)
- Hwang H, "Transmission dynamics of the delta variant of SARS-CoV-2 infections in South Korea", J Infect Dis, 225(5), pp.793~799 (2022)
- Florensa D, "Severity of COVID-19 cases in the months of predominance of the Alpha and Delta variants", Sci Rep, 12(1), pp.15456~ (2022)
- Hu Z, "Differences in clinical characteristics between delta variant and wild-type SARS-CoV-2 infected patients", Front Med(Lausanne), 8, pp.792135~ (2022)
- "The implementation of vaccination in the context of combating corona virus disease 2019 pandemic (COVID-19)" (2021)[URL]
- Tanriover MD, "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey", Lancet, 398(10296), pp.213~222 (2021)
- Sadoff J, "Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19", N Engl J Med, 384(23), pp.2187~2201 (2021)
- Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine", N Engl J Med, 383(27), pp.2603~2615 (2020)
- Heath PT, "Safety and efficacy of NVX-CoV2373 Covid-19 vaccine", N Engl J Med, 385(13), pp.1172~1183 (2021)
- Viveiros-Rosa SG, "The race for clinical trials on Omicron-based COVID-19 vaccine candidates : updates from global databases", Narra J, 2(3), pp.e88~ (2022)
- Brosh-Nissimov T, "BNT162b2 vaccine breakthrough : clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel", Clin Microbiol Infect, 27(11), pp.1652~1657 (2021)
- Sadarangani M, "Immunological mechanisms of vaccine-induced protection against COVID-19 in humans", Nat Rev Immunol, 21(8), pp.475~484 (2021)
- Henkens MT, "Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study", BMC Geriatr, 22(1), pp.184~ (2022)
- Izcovich A, "Prognostic factors for severity and mortality in patients infected with COVID-19 : a systematic review", PLoS One, 15(11), pp.e0241955~ (2020)
- "Effectiveness of the inactivated COVID-19 vaccine (CoronaVac) in adult population in Bali, Indonesia" (2022)[URL]
- Cahyani I, "Genome profiling of SARS-CoV-2 in Indonesia, ASEAN and the neighbouring East Asian countries: features, challenges and achievements", Viruses, 14(4), pp.778~ (2022)
- "4th COVID-19 guidelines of the Indonesian Society of Pulmonology (PDPI), the Indonesian Cardiovascular Association (PERKI), the Indonesian Society of Internal Medicine (PAPDI), the Indonesian Society of Anesthesiology and Intensive Therapy (PERDATIN), and the Indonesian Pediatric Society (IDAI)" (2022)[URL]
- Patel MD, "Association of simulated COVID-19 vaccination and nonpharmaceutical interventions with infections, hospitalizations, and mortality", JAMA Netw Open, 4(6), pp.e2110782~ (2021)
- Lurie N, "Developing Covid-19 vaccines at pandemic speed", N Engl J Med, 382(21), pp.1969~1973 (2020)
- Nugraha RR, "Accelerating Indonesian COVID-19 vaccination rollout : a critical task amid the second wave", Trop Med Health, 49(1), pp.76~ (2021)
- Morley JE, "A simple frailty questionnaire(FRAIL)predicts outcomes in middle aged African Americans", J Nutr Health Aging, 16(7), pp.601~608 (2012)
- "PAPDI recommendations on the administration of COVID-19 vaccination in patients with comorbidities" (2021)[URL]
- Rosiello DF, "Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America", Narra J, 1(3), pp.e55~ (2021)
- Sugiri AH, "Determinants of COVID-19 vaccine hesitancy: a community-based study in Dumai City, Riau Province, Indonesia", Open Access Maced J Med Sci, 10(E), pp.1420~1425 (2022)
- Harapan H, "Acceptance of a COVID-19 vaccine in Southeast Asia : a cross-sectional study in Indonesia", Front Public Health, 8, pp.381~ (2020)
- Utami A, "Determinant factors of COVID-19 vaccine hesitancy among adult and elderly population in Central Java, Indonesia", Patient Prefer Adherence, 16, pp.1559~1570 (2022)
- Jara A, "Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile", N Engl J Med, 385(10), pp.875~884 (2021)
- Li XN, "Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou : a test-negative case-control real-world study", Emerg Microbes Infect, 10(1), pp.1751~1759 (2021)
- Pormohammad A, "Effectiveness of COVID-19 vaccines against Delta(B. 1. 617. 2)variant : a systematic review and meta-analysis of clinical studies", Vaccines(Basel), 10(1), pp.23~ (2021)
- Tang P, "BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar", Nat Med, 27(12), pp.2136~2143 (2021)
- Watson OJ, "Global impact of the first year of COVID-19 vaccination : a mathematical modelling study", Lancet Infect Dis, 22(9), pp.1293~1302 (2022)
- "IDF diabetes atlas 10th edition" (2021)[URL]
- Song J, "Clinical course and risk factors of fatal adverse outcomes in COVID-19 patients in Korea : a nationwide retrospective cohort study", Sci Rep, 11(1), pp.10066~ (2021)
- Wang S, "Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes : a multi-centre retrospective study", Diabetologia, 63(10), pp.2102~2111 (2020)
- de Almeida-Pititto B, "Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis", Diabetol Metab Syndr, 12, pp.75~ (2020)
- Unnikrishnan R, "Diabetes and COVID19 : a bidirectional relationship", Nutr Diabetes, 11(1), pp.21~ (2021)